A pyrazole compound with improved lipid metabolism, triglyceride level reducing activity and a preparation method and application thereof

By developing novel pyrazole compounds to activate the AMPK-ACC signaling axis and regulate SREBP-1 homeostasis, the problems of single target and toxic side effects of existing lipid-lowering drugs have been solved, achieving the effect of effectively reducing triglycerides and improving lipid metabolism.

CN123106535APending Publication Date: 2026-11-17YUNNAN MINZU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611332605.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-31
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing lipid-lowering drugs suffer from single target, insufficient specificity, significant toxic side effects, and limited applicable population. Furthermore, small molecule lipid-lowering candidate compounds have simple structures and cannot effectively improve lipid metabolism disorders and hypertriglyceridemia.

Method used

To develop a novel pyrazole compound that activates the AMPK-ACC signaling axis, regulates SREBP-1 homeostasis, inhibits excessive triglyceride synthesis, and improves lipid metabolism disorders.

Benefits of technology

It significantly reduces triglyceride levels, improves lipid metabolism, and intervenes in metabolic diseases such as hypertriglyceridemia and non-alcoholic fatty liver disease, avoiding the safety issues of traditional drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106535A_ABST
    Figure CN123106535A_ABST
Patent Text Reader

Abstract

The application discloses a pyrazole compound with lipid metabolism improving and triglyceride level reducing activity, and a preparation method and application thereof. The structural formula of the pyrazole compound with lipid metabolism improving and triglyceride level reducing activity is as follows: The compound of the application is a novel pyrazole derivative. In view of the defects that existing triglyceride reducing drugs have great toxic and side effects, weak targeting, and there are few pyrazole drugs with lipid metabolism regulating activity on the market, the application aims to provide a novel pyrazole small molecule and a pharmaceutically acceptable salt thereof. By regulating the de novo fatty acid synthesis pathway, the pyrazole compound can inhibit the excessive synthesis of triglyceride and the accumulation of intracellular lipid, improve the body lipid metabolism disorder, realize the intervention on metabolic diseases such as hypertriglyceridemia and non-alcoholic fatty liver, and make up for the safety problem of traditional lipid-lowering drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medicinal chemistry technology, specifically relating to a pyrazole compound with activity in improving lipid metabolism and reducing triglyceride levels, as well as its preparation method and application. Background Technology

[0002] With the changing lifestyles of modern residents, excessive intake of high-fat and high-sugar diets and a continuous decline in daily physical activity have led to a significant increase in the incidence of lipid metabolism disorders. When the body's total energy intake exceeds the energy expenditure of basal metabolism and daily activities, excess carbohydrates can be converted into acetyl-CoA in liver cells through glycolysis and the citrate-pyruvate cycle. In addition, some amino acids can also enter the tricarboxylic acid cycle after deamination. Both types of substances provide a carbon skeleton, which is used to synthesize fatty acids through the de novo lipogenesis (DNL) pathway. These fatty acids are further esterified to form triacylglycerol (TAG), which ultimately accumulates in adipose tissue as lipid droplets. Excess triacylglycerol cannot be completely metabolized and utilized by the body, and thus is deposited in large quantities in the liver, adipose tissue, and peripheral tissues as lipid droplets, ultimately leading to dyslipidemia, ectopic lipid deposition, and systemic metabolic disorders.

[0003] Abnormal accumulation of triglycerides is one of the core pathological features of lipid metabolism disorders. Persistent hypertriglyceridemia can not only induce metabolic diseases such as obesity, non-alcoholic fatty liver, metabolic syndrome, and insulin resistance, but is also an independent risk factor for serious cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary heart disease, and stroke, placing a heavy burden on public health.

[0004] Currently, the mainstream drugs used clinically to improve lipid metabolism disorders mainly include statins, fibrates, niacin, and Omega-3 fatty acid preparations. Among them, statins primarily lower cholesterol, with limited effect on lowering triglycerides; fibrates have strong triglyceride-lowering activity, but long-term use can easily cause liver and kidney damage, myalgia, rhabdomyolysis, and gastrointestinal adverse reactions, and some patients experience drug tolerance and poor efficacy; niacin has significant side effects, with adverse reactions such as flushing and itching leading to poor patient compliance. Existing lipid-lowering drugs generally suffer from drawbacks such as single target, insufficient specificity, significant toxic side effects, and limited applicable populations. Furthermore, existing small-molecule lipid-lowering drugs have relatively simple skeletal structures, and there is still a lack of highly active, low-toxicity, and structurally novel lipid-lowering candidate compounds.

[0005] Recent studies have shown that pyrazole compounds exhibit promising potential in the prevention and treatment of metabolic diseases. Some pyrazole derivatives can improve insulin resistance and lower blood glucose and lipid levels by activating signaling pathways such as AMPK-PPAR. For example, certain pyrazole-pyrimidine compounds have been reported as effective AMPK activators, inhibiting hepatocyte lipid synthesis and promoting fatty acid oxidation. Furthermore, pyrazole-containing PPARα / γ dual agonists have shown superior synergistic effects in improving lipid metabolism disorders compared to single-target drugs. Due to their high structural modifiability, pyrazole compounds can be optimized to achieve better pharmacokinetic properties and target selectivity, making them an important direction for drug development in metabolic diseases.

[0006] Therefore, developing a class of pyrazole compounds with novel structures, simple synthesis, strong lipid-lowering activity, and high safety to target the de novo synthesis of fatty acids and inhibit abnormal accumulation of triglycerides is of great theoretical value and clinical application prospects for developing new anti-hypertriglyceridemia drugs, making up for the deficiencies of existing technologies, and meeting unmet clinical needs. Summary of the Invention

[0007] The first objective of this invention is to provide a pyrazole compound with activity of improving lipid metabolism and reducing triglyceride levels; the second objective is to provide the application of the pyrazole compound with activity of improving lipid metabolism and reducing triglyceride levels.

[0008] The first objective of this invention is achieved as follows: the structural formula of the pyrazole compound having the activity of improving lipid metabolism and reducing triglyceride levels is as follows: .

[0009] The second objective of this invention is achieved by using the pyrazole compounds, which have the activity of improving lipid metabolism and reducing triglyceride levels, in the preparation of drugs that regulate lipid metabolism.

[0010] The compounds of this invention are novel pyrazole derivatives. Addressing the shortcomings of existing triglyceride-lowering drugs, such as significant toxicity and weak targeting, and the scarcity of pyrazole drugs with lipid metabolism regulatory activity on the market, this invention aims to provide a novel pyrazole small molecule and its pharmaceutically acceptable salt. By regulating the de novo fatty acid synthesis pathway, it inhibits excessive triglyceride synthesis and lipid accumulation in tissues, improves lipid metabolism disorders, and intervenes in metabolic diseases such as hypertriglyceridemia and non-alcoholic fatty liver disease, thus overcoming the safety deficiencies of traditional lipid-lowering drugs.

[0011] The compounds in this invention activate the AMPK-ACC signaling axis in a dose-dependent manner and regulate lipid metabolism by modulating SREBP-1 homeostasis. Attached Figure Description

[0012] Figure 1 This is a schematic diagram illustrating the effect of the compound of the present invention on the triglyceride (TG) content in a high-fat model nematode; By measuring its content in nematodes, it is possible to directly determine whether the lipid accumulation model has been successfully established, and also to determine whether lipid accumulation in nematodes is reduced or aggravated after treatment with drugs or compounds. (Con: blank control group, Mod: model group, FNB: fenofibrate group, values ​​are expressed as mean ± standard error, * indicates the degree of significance, compared with the model group: **P<0.01, ***P<0.001, compared with the model group, ns indicates no significant difference, # indicates the degree of significance, compared with the blank control group: ###P<0.001, n = 3); Figure 2 This is a schematic diagram illustrating the effect of the compound of the present invention on the fat content in a high-fat model nematode. in, Figure 2 Figure 'a' shows a schematic diagram of each group of nematodes after Oil Red O staining. The staining area is used to assess lipid accumulation in the nematodes; a larger staining area indicates greater lipid accumulation. Figure 2 After data quantification of Oil Red O-stained images of α, the dose-response relationship of pyrazole compound (I) in reducing the fat content in hyperlipidemic nematodes was obtained as follows: Figure 2 b indicates; (a: Schematic diagram of Oil Red O staining, b: Quantitative diagram of Oil Red O staining. Con: Blank control group, Mod: Model group, FNB: Fenofibrate group. Values ​​are expressed as mean ± standard error. * indicates the degree of significance. Compared with the model group: **P<0.01, ***P<0.001. Compared with the model group, ns indicates no significant difference. # indicates the degree of significance. Compared with the blank control group: ###P<0.001, n = 3). Figure 3 This is a schematic diagram illustrating the effect of the compound of the present invention on the content of free fatty acids (FFA) in a high-lipid model nematode; (Con: blank control group, Mod: model group, FNB: fenofibrate group, values ​​are expressed as mean ± standard error, * indicates the degree of significance, compared with the model group: *** P < 0.001, compared with the model group, ns indicates no significant difference, # indicates the degree of significance, compared with the blank control group: ### P < 0.001, n = 3); Figure 4 This is a schematic diagram illustrating the effect of the compound of the present invention on the expression level of p-AMPK protein in a high-lipid model nematode; The effects of different concentrations of pyrazole compound (I) (25, 50, 100 μg / mL) on the phosphorylation levels of key proteins in the AMPK pathway were detected by Western blot. (Con: blank control group, Mod: model group, FNB: fenofibrate group, values ​​are expressed as mean ± standard error, compared with the model group, ns indicates no significant difference, * indicates the degree of significance, compared with the model group: ***P<0.001, n = 3). Figure 5 This is a schematic diagram illustrating the effect of the compounds of this invention on triglyceride levels in HepG2 cells induced by high-lipid intake. (Con: blank control group, Mod: model group, FNB: fenofibrate group, values ​​are expressed as mean ± standard error, * indicates the degree of significance, compared with the model group: *) P <0.05,** P <0.01, # indicates the degree of statistical significance, compared with the blank control group: ### P <0.001, n = 3); Figure 6 This is a schematic diagram illustrating the effect of the compounds of the present invention on the expression levels of lipid metabolism-related proteins in high-lipid HepG2 cells; To investigate the effect of pyrazole compound (I) on the AMPK signaling pathway, the expression and phosphorylation levels of AMPK protein in each group of cells were examined. (Con: blank control group, Mod: model group, FNB: fenofibrate group, values ​​are expressed as mean ± standard error, compared with the model group, ns indicates no significant difference, * indicates the degree of significance, compared with the model group: *P<0.05, **P<0.01, ***P<0.001, n = 3). Detailed Implementation

[0013] The present invention will be further described below with reference to embodiments, but this is not intended to limit the present invention in any way. Any modifications or substitutions made based on the teachings of the present invention shall fall within the protection scope of the present invention.

[0014] The structural formula of the pyrazole compound with activities to improve lipid metabolism and reduce triglyceride levels described in this invention is as follows: .

[0015] The application of this invention is the use of the pyrazole compounds, which have the activity of improving lipid metabolism and reducing triglyceride levels, in the preparation of drugs that regulate lipid metabolism.

[0016] The present invention will be further described below with reference to specific embodiments: Example 1

[0017] The structural formula of the compound of the present invention is shown in formula (I): .

[0018] Experimental study on the effect of pyrazole compound (I) of this invention on lipid accumulation levels in Caenorhabditis elegans: Experimental instruments: stereomicroscope (Yunnan Keyi Chemical Glass, China), ultrapure water system (Chengdu Shenyuan, China), clean bench (Suzhou Jiabao Purification, China), biochemical incubator (Guangdong Taihongjun, China), fully automatic autoclave (Sanyo, Japan), pipette (Eppendorf, Germany), ultra-low temperature freezer (Haier, China).

[0019] Experimental reagents: Sodium hydroxide (Sichuan Xilong Chemical, China), anhydrous calcium chloride (Sichuan Xilong Chemical, China), potassium dihydrogen phosphate (Sichuan Xilong Chemical, China), 5-fluoro-2'-deoxyuridine (Maclean's, China), cholesterol (Maclean's, China), EDTA·Na2 (Solepro, China), agar powder (Solepro, China), manganese chloride (Tianjin Fengchuan Chemical, China), copper sulfate (Tianjin Fengchuan Chemical, China), glycerol (Lanjieke, China), dimethyl sulfoxide (Biosharp, China), insect picking needle (Fujian Shangyuan Biotechnology, China), sterile bacterial culture dish (Lanjieke, China). Triglyceride (TG) assay reagent (Nanjing Jiancheng, China), Oil Red O dry powder (Sigma, USA), isopropanol (Beyotime, China), 4% paraformaldehyde fixative (Wuhan Kanos, China), free fatty acid (FFA) assay kit (Sangon Biotech, China), BCA protein assay kit (Thermo, USA).

[0020] Experimental Methods: In this study, *C. elegans* was cultured in an incubator at 20 ℃ and synchronized before the experiment. High-glucose NGM plates were prepared by mixing autoclaved NGM medium with sterile filtered glucose solution (final concentration 250 mM) and cooled to 4 ℃ for later use.

[0021] After synchronization, nematodes that have grown to the L4 stage were transferred at a density of 2000-3000 nematodes per plate to a new high-glucose NGM plate coated with E. coli OP50. After culturing for 4 days, the nematodes were washed off the plate with M9 buffer and transferred to 1.5 mL EP tubes. The tubes were allowed to stand for 3-5 minutes to allow the nematodes to settle naturally, and the supernatant was removed. The washing was repeated 4-5 times until the liquid was clear, and the nematodes were collected. The washed nematodes were transferred to the following experimental plates coated with E. coli OP50: (1) ordinary NGM (blank control group), (2) normal high-glucose NGM (model group), (3) high-glucose NGM containing 100 μg / mL fenofibrate (positive control group), (4) high-glucose NGM containing 25 μg / mL of the compound of the present invention, PZ176, (5) high-glucose NGM containing 50 μg / mL pyrazole compound (I), and (6) high-glucose NGM containing 100 μg / mL PZ176. The plates were changed every two days during the treatment period, and the treatment continued for 3 days. Nematode samples were then collected, and the protein concentration of each sample was determined using the BCA method. The triglyceride content in each group of nematodes was also detected according to the instructions of the TG test kit from Nanjing Jiancheng Bioengineering Research Institute Co., Ltd. The triglyceride content was calculated using the following formula: Triglyceride content (mM / gprot) = (A sample well - A blank well) / (A standard well - A blank well) × C standard / Cpro Where A is the absorbance value; Cpr is the protein concentration of the homogenate of the tissue sample to be tested, gprot / L; and C standard is the concentration of the standard.

[0022] After synchronization, nematodes that have grown to the L4 stage were transferred at a density of 2000-3000 nematodes per plate to a new high-glucose NGM plate coated with E. coli OP50. After culturing for 4 days, the nematodes were washed off the plate with M9 buffer and transferred to 1.5 mL EP tubes. The tubes were allowed to stand for 3-5 minutes to allow the nematodes to settle naturally, and the supernatant was removed. The washing was repeated 4-5 times until the liquid was clear, and the nematodes were collected. The washed nematodes were transferred to the following experimental plates coated with E. coli OP50: (1) ordinary NGM (blank control group), (2) normal high-glucose NGM (model group), (3) high-glucose NGM containing 100 μg / mL fenofibrate (positive control group), (4) high-glucose NGM containing 25 μg / mL pyrazole compound (I), (5) high-glucose NGM containing 50 μg / mL PZ176, and (6) high-glucose NGM containing 100 μg / mL of the compound of the present invention, PZ176. The plates were changed every two days during the treatment period, and the treatment continued for 3 days. Afterward, the parasites were collected, and 150 μl of 4% paraformaldehyde was added to each tube for fixation at room temperature for 15 minutes. Following fixation, a freeze-thaw cycle was used: the sample was frozen at -80 ℃ for 2 minutes, followed by thawing in a water bath at room temperature for 1 minute, and this cycle was repeated 3 times. After 3 cycles, the sample was washed 3 times with M9 buffer, and the supernatant was discarded. 1 mL of 60% isopropanol was added for dehydration for 10 minutes, followed by centrifugation at 3000 rpm for 30 s, and the supernatant was removed. 200 μl of Oil Red O working solution was added to each tube, and the sample was stained in the dark for 30–60 minutes. After staining, the sample was washed with 100% isopropanol for 3 minutes until completely destained. Finally, the supernatant was transferred to a 96-well plate, and the absorbance was measured at 492 nm using a microplate reader to quantify lipid deposition levels.

[0023] Take nematodes that have matured to the L4 stage after synchronization and transfer them at a density of 2000-3000 nematodes per plate to a new high-glucose NGM plate coated with E. coli OP50. After culturing for 4 days, wash the nematodes off the plate with M9 buffer and transfer them to 1.5 mL EP tubes. Let them stand for 3-5 minutes to allow the nematodes to settle naturally and remove the supernatant. Repeat the washing process 4-5 times until the liquid is clear and collect the nematodes. After washing, the nematodes were transferred to the following experimental plates coated with E. coli OP50: (1) ordinary NGM (blank control group), (2) normal high-glucose NGM (model group), (3) high-glucose NGM containing 100 μg / mL fenofibrate (positive control group), (4) high-glucose NGM containing 25 μg / mL PZ176, (5) high-glucose NGM containing 50 μg / mL PZ176, and (6) high-glucose NGM containing 100 μg / mL PZ176. The plates were changed every two days during the treatment period, and the treatment was continued for 3 days. After that, the nematode samples were collected, and the protein concentration of each sample was determined by the BCA method. The free fatty acid content in each tube of nematode was determined according to the instructions of the free fatty acid kit. The free fatty acid content was calculated according to the following formula: ΔAstandard = Astandard tube - Ablank tube ΔAdetermination = Adetermination tube - Acontrol tube Plot a standard curve with the concentration of the standard solution as the X-axis and ΔA as the Y-axis. Substitute the ΔA measurement value into the equation based on the standard curve to obtain χ (μM).

[0024] FFA content (μmol / mg prot) = χ × V total sample (Cpr × V total sample) = χ / Cpr Vsample total: Total volume of supernatant, 1 mL; Cpr: Protein concentration of sample, mg / mL.

[0025] Example 2

[0026] Experimental study on the effect of the pyrazole compound (I) of this invention on the expression level of p-AMPK protein in a high-lipid model nematode: Experimental instruments: stereomicroscope (Yunnan Keyi Chemical Glass, China), ultrapure water system (Chengdu Shenyuan, China), clean bench (Suzhou Jiabao Purification, China), biochemical incubator (Guangdong Taihongjun, China), fully automatic autoclave (Sanyo, Japan), pipette (Eppendorf, Germany), ultra-low temperature freezer (Haier, China), electrophoresis apparatus (Wealtec, USA), protein electrophoresis / transfer tank (BIO RAD, USA), chemiluminescent fluorescent gel imaging system (UVITEC CAMBRIDGE, UK), constant temperature metal bath (Wealtec, USA).

[0027] Experimental reagents: Sodium hydroxide (Sichuan Xilong Chemical, China), anhydrous calcium chloride (Sichuan Xilong Chemical, China), potassium dihydrogen phosphate (Sichuan Xilong Chemical, China), 5-fluoro-2'-deoxyuridine (Maclean's, China), cholesterol (Maclean's, China), EDTA·Na2 (Solepro, China), agar powder (Solepro, China), manganese chloride (Tianjin Fengchuan Chemical, China), copper sulfate (Tianjin Fengchuan Chemical, China), glycerol (Lanjieke, China), dimethyl sulfoxide (Biosharp, China), insect picking needle (Fujian Shangyuan Biotechnology, China), sterile bacterial culture dish (Lanjieke, China), 10% Express Cast PAGE Gel Preparation Kit (NewSmithKline, China), ECL chemiluminescence detection kit (Abixin, China), methanol (Yunnan Liyan, China), RIPA lysis buffer (Beyotime, China), Tween-20 (Solepro, China), skim milk powder (Wandashan, China), electrophoresis and transfer buffer (dry powder) (Saiwell, China), medical X X-ray film (Raycus, China), X-ray film developer (Nuoxiang, China), X-ray film fixer (Nuoxiang, China), X-ray photography cassette (Guangdong Yuehua, China), β-Actin rabbit mAb (Sanying, China), Goat Anti-Rabbit IgG (Sanying, China), Goat Anti-Mouse IgG (Sanying, China), AMPK rabbit mAb (Cell Signaling Technology, USA), phospho-AMPKα (Thr172) rabbit mAb (Cell Signaling Technology, USA), 2-APB (Aladdin, China), Xanthine (Aladdin, China).

[0028] Experimental methods: (1) Protein sample extraction and collection In this study, *C. elegans* was cultured in a 20 ℃ incubator and synchronized before the experiment.

[0029] High-glucose NGM plates were prepared by mixing autoclaved NGM medium with sterile filtered glucose solution (final concentration 250 mM) and cooling them to 4 ℃ for later use. Nematodes that had reached the L4 stage after synchronization were transferred at a density of 2000-3000 nematodes per plate to new high-glucose NGM plates coated with E. coli OP50. After 4 days of incubation, the nematodes were washed off the plates using M9 buffer and transferred to 1.5 mL EP tubes. The tubes were allowed to settle naturally for 3–5 minutes, and the supernatant was removed. This washing process was repeated 4–5 times until the liquid was clear, and the nematodes were collected. After washing, the nematodes were transferred to the following experimental plates coated with E. coli OP50: (1) ordinary NGM (blank control group), (2) normal high-glucose NGM (model group), (3) high-glucose NGM containing 100 μg / mL fenofibrate (positive control group), (4) high-glucose NGM containing 25 μg / mL PZ176, (5) high-glucose NGM containing 50 μg / mL PZ176, and (6) high-glucose NGM containing 100 μg / mL PZ176. The plates were changed every two days during the treatment period. After three days of continuous treatment, nematode protein samples were collected, and the protein concentration was determined by the BCA method. The samples were mixed with 4x Loading Buffer at a ratio of 3:1 and heated in a 97 ℃ metal bath for 10 minutes to denature the protein. After programmed cooling, the samples were stored at -20 ℃ for short-term storage or -80 ℃ for long-term storage.

[0030] (2) Western blot Based on the molecular weight of the target protein, this study used a 10% SDS-PAGE gel, and the specific preparation method is as follows: ① Preparation of the lower gel layer: Take a clean glass plate, place it firmly on the gel casting stand, and check for leaks with distilled water to ensure there are no leaks. Accurately measure 2.5 mL each of the lower gel solution and the lower gel buffer solution, and mix them thoroughly. Then add 50 μl of modified coagulant to the mixture, and mix thoroughly again to obtain the lower gel working solution. Pour the prepared solution into the gel casting plate, add an appropriate amount of alcohol or water, press the gel to separate it, and wait for the lower gel to solidify (5-15 minutes). Discard the upper layer of water or alcohol, and use filter paper to absorb excess water or alcohol.

[0031] ② Preparation of the top layer gel: Measure equal volumes of 0.75 mL of the top layer gel solution and 0.75 mL of the colored top layer gel buffer, mix gently, and add 15 μl of the modified coagulant to the mixture, then mix well. Pour the prepared solution into the gel casting plate, and then slowly insert the sample comb, avoiding the formation of air bubbles. After the top layer gel has completely solidified, carefully remove the comb, and then proceed with the subsequent sample loading operations.

[0032] ③ Sample loading: The protein concentration of the sample to be tested is determined by the BCA method, and the sample volume is calculated according to the concentration. The corresponding marker and sample to be tested are added to the sample well in the predetermined order.

[0033] ④ Electrophoresis: After loading the sample, add electrophoresis buffer until it is flush with the wells of the glass plate. Perform compression electrophoresis at 80V. After the compression gel is completed, increase the pressure to 120V to separate the proteins of the corresponding size. Electrophoresis is complete when bromophenol blue runs out of the bottom of the gel.

[0034] ⑤ Wet Transfer: Prepare the transfer buffer in advance and pre-chill it at 4°C. Cut the PVDF membrane to the size of the target protein, activate it in methanol for 1 minute, and then transfer it into the transfer buffer for 3–5 minutes. After disassembling the electrophoresis tank, remove the gel and cut off the stacking gel. Assemble the transfer system using a "sandwich" structure, avoiding air bubbles during the transfer process. Add the pre-chilled transfer buffer to the transfer tank, place ice packs inside the tank, and supplement the outside with a large amount of ice-water mixture. Turn on the power, set the current to 200 mA, and continue the transfer for 100 minutes to complete the transfer.

[0035] ⑥ Blocking: After transfer, remove the PVDF membrane and wash it three times with PBST at 180 rpm on a shaker for 5 minutes each time. Then add blocking buffer and block at room temperature with a shaker at 180 rpm for 2 hours. After blocking, wash the membrane three more times with PBST at 180 rpm on a shaker (5 minutes each time) until the milk is removed. Finally, cut the membrane according to the molecular weight of the target protein.

[0036] ⑦ Primary antibody incubation: Dilute the corresponding protein antibody according to the antibody instructions, add the cut PVDF membrane to the primary antibody dilution solution, and incubate overnight on a shaker at 4 ℃.

[0037] ⑧ Secondary antibody incubation: After primary antibody incubation, wash the membrane three times with PBST on a shaker at 180 rpm for 5 minutes each time. Add the corresponding secondary antibody dilution buffer and incubate on a shaker at room temperature for 2 hours.

[0038] ⑨ Development: Wash the membrane three times with PBST on a shaker at 180 rpm for 5 minutes each time. After washing, place the membrane in PBST for later use. Mix ECL chemiluminescence solution 1:1, drop the membrane, and collect images using an X-ray film or CCD imager in a dark room.

[0039] Example 3

[0040] Experimental study on the cytotoxicity of the pyrazole compound (I) of this invention against high-lipid-induced HepG2 cells: Experimental instruments: Ordinary inverted optical microscope (Leica, Germany), ultrapure water system, clean bench (Thermo, USA), low-temperature storage box (Haier, China), fully automatic autoclave (Hirayama, Japan), cell carbon dioxide incubator (Thermo, USA), pipette (Eppendorf, Germany), microplate reader (Thermo, USA), electronic balance (Denver Instruments, USA), ultra-low temperature freezer (Haier, China).

[0041] Experimental reagents: DMEM medium (Biological Industries, Israel), fetal bovine serum (Biological Industries, Israel), streptomycin / penicillin (Biological Industries, Israel), 0.25% trypsin (Biological Industries, Israel), 96-well cell culture plates (NEST), DMSO (Sigma, USA), PBS, cell cryopreservation tubes (Thermo, USA), cell culture dishes (Thermo, USA), centrifuge tubes (Corning, USA), MTT assay kit for cell proliferation and cytotoxicity (Nanjing Jiancheng, China), DMSO (Solepro, China).

[0042] Experimental Methods: This study used the HepG2 cell line and detected the effects of pyrazole compound (I) on cell proliferation and cytotoxicity using the MTT assay. The nutrient system for each group was prepared using high-glucose DMEM containing 10% FBS. The experimental groups were as follows: (1) Blank control group: high-glucose DMEM medium containing 10% FBS; (2) Experimental group: high-glucose DMEM medium containing 10% FBS plus PZ176 at various concentration gradients (3.125, 6.25, 12.5, 25, 50, 100 μM); each group had 3 replicates, and were cultured at 37 ℃ in a 5% incubator for 24 h. Following the instructions of the cell proliferation and cytotoxicity detection kit from Nanjing Jiancheng Biotechnology Research Institute Co., Ltd., the supernatant of the culture medium was removed, and MTT working solution was added. The cells were incubated at 37 ℃ for 4 h, the supernatant was removed, and DMSO was added to dissolve and crystallize the cells. The absorbance was measured at 570 nm using a microplate reader, and the cell viability was calculated using the following formula: Cell viability % = (A with drug - A blank) / (A control - A blank) × 100% A. Drug addition: OD value of the experimental group A. Control: Blank control group OD value A. Blank: Solvent OD value Example 4

[0043] Experimental study on the effect of pyrazole compound (I) of the present invention on lipid metabolism induced by high lipid levels in HepG2 cells: Experimental instruments: Ordinary inverted optical microscope (Leica, Germany), ultrapure water system, clean bench (Thermo, USA), low-temperature storage box (Haier, China), fully automatic autoclave (Hirayama, Japan), cell carbon dioxide incubator (Thermo, USA), pipette (Eppendorf, Germany), microplate reader (Thermo, USA), electronic balance (Denver Instruments, USA), ultra-low temperature freezer (Haier, China).

[0044] Experimental reagents: DMEM medium (Biological Industries, Israel), fetal bovine serum (Biological Industries, Israel), streptomycin / penicillin (Biological Industries, Israel), 0.25% trypsin (Biological Industries, Israel), 96-well cell culture plates (NEST), DMSO (Sigma, USA), PBS, cell cryopreservation tubes (Thermo, USA), cell culture dishes (Thermo, USA), centrifuge tubes (Corning, USA).

[0045] Experimental Methods: HepG2 human hepatocellular carcinoma cells were purchased from the American Type Culture Collection. All cell culture systems in this study were supplemented with 1% penicillin-streptomycin (P / S). HepG2 cells were monolayered and adherent in high-glucose DMEM medium containing 10% fetal bovine serum (FBS). When HepG2 cells reached 80%-90% confluence, they were seeded in 24-well plates at a density of 8 × 10³ cells / well.

[0046] To induce intracellular lipid accumulation, an in vitro lipid metabolism imbalance model was constructed by treating cells with a mixed solution of palmitic acid and sodium oleate. The specific experimental steps were as follows: 12.5 μl of a mixed solution of sodium palmitate:sodium oleate:BSA (final molar ratio 20 mM : 10 mM : 20% BSA) was added to 500 μl of high-glucose DMEM medium containing 10% FBS. This mixture was then added to 24-well plates seeded with HepG2 cells and cultured for 24 h to establish a HepG2 cell lipid accumulation model for subsequent experiments.

[0047] The HepG2 lipid accumulation cell model was used for experiments. High-glucose DMEM culture system with 10% FBS was used to prepare the culture systems for each group. The experimental groups were as follows: (1) Blank control group: no adipogenesis modeling, high-glucose DMEM culture medium containing 10% FBS; (2) Model group: high-glucose DMEM culture medium containing 10% FBS; (3) Positive control group: 50 μM fenofibrate; (4) Experimental group: PZ176 (25, 50, 100 μM). Each group had two biological replicates and was cultured at 37 ℃ in a 5% CO2 incubator for 24 h. The triglyceride content in each group was detected according to the instructions of the TG test kit from Nanjing Jiancheng Biotechnology Research Institute Co., Ltd. The triglyceride content was calculated using the following formula: Triglyceride content (mmol / 10) 8 (cell) = (A sample well - A blank well) / (A standard well - A blank well) × C standard / C cells (A is the absorbance value, C standard = 2.68 mM, C cells: cell density) Example 5

[0048] Experimental study on the effect of pyrazole compound (I) of this invention on the expression levels of lipid metabolism-related proteins in high-lipid HepG2 cells: Experimental instruments: Ordinary inverted optical microscope (Leica, Germany), ultrapure water system, clean bench (Thermo, USA), low-temperature storage box (Haier, China), fully automatic autoclave (Hirayama, Japan), cell carbon dioxide incubator (Thermo, USA), pipette (Eppendorf, Germany), microplate reader (Thermo, USA), electronic balance (Denver Instruments, USA), ultra-low temperature freezer (Haier, China), protein electrophoresis apparatus (Bio-Rad), protein colorimetric equipment.

[0049] Experimental reagents: DMEM medium (Biological Industries, Israel), fetal bovine serum (Biological Industries, Israel), streptomycin / penicillin (Biological Industries, Israel), 0.25% trypsin (Biological Industries, Israel), 96-well cell culture plates (NEST), DMSO (Sigma, USA), PBS, cell cryopreservation tubes (Thermo, USA), cell culture dishes (Thermo, USA), centrifuge tubes (Corning, USA), MTT assay kit for cell proliferation and cytotoxicity (Nanjing Jiancheng, China), DMSO (Solepro, China), ultrapure water, 10% ExpressCast PAGE Gel Preparation kit, color gel rapid assay kit (Synthetic, China), ECL chemiluminescence assay kit (Abixin, China), methanol (Yunnan Liyan, China), RIPA lysis buffer (Beyotime, China), Tween-20 (Solepro, China), skim milk powder (Wandashan, China), electrophoresis buffer, transfer buffer, PVDF membrane.

[0050] Experimental methods: (1) Protein collection: Discard the culture medium in the wells, gently wash the cells twice with pre-cooled PBS, aspirate the residual liquid, add 200 μl of cell lysis buffer to each well of a 24-well plate, lyse on ice for 30 minutes, and pipette every 5 minutes. Use a sterile cell scraper to thoroughly scrape the cells attached to the bottom of the wells, transfer the lysis mixture containing cell debris to a pre-cooled 1.5 ml EP tube, add 50 ml of 5× loading buffer to each tube, and then heat in a metal bath at 100°C for 10 minutes. After the process, store at -80°C.

[0051] (2) Based on the molecular weight of the target protein, this study used a 10% SDS-PAGE gel, and the specific preparation method is as follows: ① Preparation of the lower gel layer: Take a clean glass plate, place it firmly on the gel casting stand, and check for leaks with distilled water to ensure there are no leaks. Accurately measure 2.5 mL each of the lower gel solution and the lower gel buffer solution, and mix them thoroughly. Then add 50 μl of modified coagulant to the mixture, and mix thoroughly again to obtain the lower gel working solution. Pour the prepared solution into the gel casting plate, add an appropriate amount of alcohol or water, press the gel to separate it, and wait for the lower gel to solidify (5-15 minutes). Discard the upper layer of water or alcohol, and use filter paper to absorb excess water or alcohol.

[0052] ② Preparation of the top layer gel: Measure equal volumes of 0.75 mL of the top layer gel solution and 0.75 mL of the colored top layer gel buffer, mix gently, and add 15 μl of the modified coagulant to the mixture, then mix well. Pour the prepared solution into the gel casting plate, and then slowly insert the sample comb, avoiding the formation of air bubbles. After the top layer gel has completely solidified, carefully remove the comb, and then proceed with the subsequent sample loading operations.

[0053] ③ Sample loading: The protein concentration of the sample to be tested is determined by the BCA method, and the sample volume is calculated according to the concentration. The corresponding marker and sample to be tested are added to the sample well in the predetermined order.

[0054] ④ Electrophoresis: After loading the sample, add electrophoresis buffer until it is flush with the wells of the glass plate. Perform compression electrophoresis at 80V. After the compression gel is completed, increase the pressure to 120V to separate the proteins of the corresponding size. Electrophoresis is complete when bromophenol blue runs out of the bottom of the gel.

[0055] ⑤ Wet Transfer: Prepare the transfer buffer in advance and pre-chill it at 4°C. Cut the PVDF membrane to the size of the target protein, activate it in methanol for 1 minute, and then transfer it into the transfer buffer for 3–5 minutes. After disassembling the electrophoresis tank, remove the gel and cut off the stacking gel. Assemble the transfer system using a "sandwich" structure, avoiding air bubbles during the transfer process. Add the pre-chilled transfer buffer to the transfer tank, place the bag inside the tank, and provide ample ice-water mixture externally. Turn on the power, set the current to 200 mA, and continue the transfer for 100 minutes to complete the transfer.

[0056] ⑥ Blocking: After transfer, remove the PVDF membrane and wash it three times with PBST at 180 rpm on a shaker for 5 minutes each time. Then add blocking buffer and block at room temperature with a shaker at 180 rpm for 2 hours. After blocking, wash the membrane three more times with PBST at 180 rpm on a shaker (5 minutes each time) until the milk is removed. Finally, cut the membrane according to the molecular weight of the target protein.

[0057] ⑦ Primary antibody incubation: Dilute the corresponding protein antibody according to the antibody instructions, add the cut PVDF membrane to the primary antibody dilution solution, and incubate overnight on a shaker at 4 ℃.

[0058] ⑧ Secondary antibody incubation: After primary antibody incubation, wash the membrane three times with PBST on a shaker at 180 rpm for 5 minutes each time. Add the corresponding secondary antibody dilution buffer and incubate on a shaker at room temperature for 2 hours.

[0059] ⑨ Development: Wash the membrane three times with PBST on a shaker at 180 rpm for 5 minutes each time. After washing, place the membrane in PBST for later use. Mix ECL chemiluminescence solution 1:1, drop the membrane, and collect images using an X-ray film or CCD imager in a dark room.

Claims

1. A pyrazole compound with activity of improving lipid metabolism and reducing triglyceride levels, characterized in that, The structural formulas of the pyrazole compounds that have the activity of improving lipid metabolism and reducing triglyceride levels are as follows: 。 2. The application of the pyrazole compound of claim 1, which has the activity of improving lipid metabolism and reducing triglyceride levels, characterized in that, The application of the pyrazole compounds, which have the activity of improving lipid metabolism and reducing triglyceride levels, in the preparation of drugs that regulate lipid metabolism.